CPAP;Heliox Effects on Stability and Therapeutics - C.H.E.S.T.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002585-11-GB

Enrollment

Registered

2005-08-03

Start date

2005-10-10

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress requiring CPAP Examples: Bronchilitis, post-exturbation, Upper Airway Obstruction...

Interventions

Trade Name: Heliox 21 Pharmaceutical Form: Trade Name: Heliox 21 Product Name: Heliox 21 Pharmaceutical Form: Inhalation gas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age less/equal then 1 year(chronological age), respiratory distress requiring CPAP Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pneumothorax, extreme respiratory failure,imminent intubation,haemodynamically unstable, FiO2>0.6

Design outcomes

Primary

Measure	Time frame
Main Objective: work of breathing;Secondary Objective: Oxygenation Carbon Dioxide clearance;Primary end point(s): Work of breathing	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026